What Fueled The Previous Growth In The Herpangina Treatment Market?
The herpangina treatment market has seen considerable growth due to a variety of factors.
•The size of the market for herpangina treatment has considerably expanded in the past few years. This market is slated to escalate from $1.86 billion in 2024 to $1.98 billion in 2025, with a compound annual growth rate (CAGR) of 6.5%.
The unprecedented expansion during the historic period is primarily due to viral outbreaks and prevalence, an upswing in the pediatric population, advances in healthcare infrastructure, public health education programs, and breakthroughs in clinical research and treatment methodologies.
What Is The Expected Growth In The Herpangina Treatment Market Size?
The herpangina treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market for herpangina treatment is projected to undergo substantial growth in the forthcoming years, expanding to "$2.68 billion by 2029 with a compound annual growth rate (CAGR) of 7.9%.
This anticipated growth during the forecast period is attributed to the appearance of new viral strains, increased emphasis on child health, global health policies, advancements in diagnostic technology, and improved healthcare accessibility. Significant trends expected within this forecast period encompass the creation of topical treatments for oral lesions, the introduction of telemedicine for diagnosis, and consultation, heightened patient education, and awareness initiatives, partnerships for clinical research and trials, as well as worldwide health readiness campaigns.
What Are The Leading Drivers Of Growth In The Herpangina Treatment Market?
The surge in research and development activities is anticipated to stimulate the expansion of the herpangina treatment market. As a viral disease, herpangina typically affects children, leading to painful sores or ulcers on the tonsils and back of the throat triggered by coxsackievirus and enteroviruses. Treatment for herpangina seeks to alleviate the severe symptoms such as blisters, high fever, mouth or throat discomfort, drooling, and loss of appetite. For example, data from the Office for National Statistics, a UK national statistical institute, show that in 2022, the UK government increased net expenditure on research and development by 10.5%, equating to £15.5 billion ($19.5 billion), compared to £14.0 billion ($17.7 billion) in 2021 in April 2024. Consequently, the surge in research and development activities is fuelling the expansion of the herpangina treatment market.
How Are The Segments Defined Within The Global Herpangina Treatment Market?
The herpangina treatment market covered in this report is segmented –
1) By Treatment: Topical Anesthetics, Ibuprofen Or Acetaminophen, Other Treatments
2) By Virus: Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71, Echovirus
3) By Symptoms: High Fever, Sore Throat, Blisters Or Ulcers In The Throat Mouth, Difficulty Swallowing, Loss Of Appetite, Neck Pain, Swollen Lymph Glands, and Headache
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Topical Anesthetics: Benzocaine, Lidocaine, Other Anesthetics
2) By Ibuprofen or Acetaminophen: Ibuprofen, Acetaminophen, Other Treatments
3) By Antiviral Medications: Corticosteroids, Supportive Care
Pre-Book The Herpangina Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Herpangina Treatment Market?
The emergence of treatment methods for herpangina conditions like aphthous stomatitis is a key trend witnessing increasing traction in the herpangina treatment market. Leading corporations in the herpangina treatment realm are creating therapies aimed at alleviating discomfort for people plagued by recurrent mouth ulcers. For example, in September 2022, Mucocort, a healthcare firm stationed in Sweden and engaged in the production of oral patches, forged an agreement with Aurena Laboratories AB, a medical technology entity also based in Sweden, resulting in a unique self-absorbing patch that provides pain relief. This distinctive patch treatment aids individuals who grapple with recurrent mouth ulcers and aphthous stomatitis by easing their pain and accelerating the aphthous ulcers' natural healing cycle.
Who Are the Key Players in the Herpangina Treatment Market?
Major companies operating in the herpangina treatment market include:
• Hoffmann-La Roche Ltd.
• Takeda Pharmaceutical Company Limited
• Pfizer Inc
• AstraZeneca
• Novartis AG
• GlaxoSmithKline Plc
• Merck & Co.
• Inc.
• AbbVie Inc.
• Eli Lilly and Company
• Bayer AG
• Sanofi
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Mucocort
• Aurena Laboratories AB
• Cipla Inc.
• Dr. Reddy’s Laboratories Ltd.
• Teva Pharmaceutical Industries Ltd.
• Zydus Cadila
• Aurobindo Pharma Ltd.
• Lupin Limited
• Glenmark Pharmaceuticals
• Sun Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• F. Hoffmann-La Roche AG
• Boehringer Ingelheim International GmbH
• Sandoz International GmbH
• Endo International plc
• Mylan N.V.
• CSL Limited.
What Is The Most Dominant Region In The Herpangina Treatment Market?
North America was the largest region in the global herpangina treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herpangina treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
